ArticleWorld journal of surgery2014
Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Article in World journal of surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma.Nutrients · 2026Article
- [Individualized curative treatment for malignant diseases through liver transplantation].Chirurgie (Heidelberg, Germany) · 2024Review
- Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.BJS open · 2022Article
- The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?International journal of biological sciences · 2022Review
- Neoadjuvant treatment strategies for hepatocellular carcinoma.World journal of gastrointestinal surgery · 2021Review
- Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology.Hepatic oncology · 2020Review
- Liver Transplantation Beyond Milan Criteria.Journal of clinical and translational hepatology · 2020Review
- Article
- Hepatocellular carcinoma - time to take the ticket.World journal of gastrointestinal surgery · 2019Review
- Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.Digestive diseases and sciences · 2019Review
- Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.World journal of hepatology · 2019Review
- Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation.Journal of cancer research and clinical oncology · 2018Article
- Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.Journal of Zhejiang University. Science. B · 2018Review
- GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.Oncology letters · 2018Article
- The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer.Annals of surgical oncology · 2017Article
- Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation.Scientific reports · 2017Article
- Hepatocellular carcinoma: when is liver transplantation oncologically futile?Translational gastroenterology and hepatology · 2017Review
- Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.World journal of hepatology · 2016Review
- Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.World journal of hepatology · 2016Article
- Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum α-fetoprotein concentration (AFP) might be a useful addition to morphologic criteria for selecting patients with hepatocellular carcinoma (HCC) for liver transplantation (LT). The aim of this study was to evaluate the role of AFP in selecting HCC patients at minimal risk of posttransplant tumor recurrence in the setting of existing criteria.
methodsThis retrospective cohort study was based on 121 HCC patients after LT performed at a single institution. AFP was evaluated as a predictor of posttransplant tumor recurrence with respect to fulfillment of the Milan, University of California, San Francisco (UCSF), and Up-to-7 criteria.
resultsThere was a nearly linear association between AFP and the risk of HCC recurrence (p < 0.001 for linear effect; p = 0.434 for nonlinear effect). AFP predicted HCC recurrence in patients (1) beyond the Milan criteria (p < 0.001; optimal cutoff 200 ng/ml); (2) within the UCSF criteria (p = 0.001; optimal cutoff 100 ng/ml) and beyond them (p = 0.015; optimal cutoff 200 ng/ml); and (3) within the Up-to-7 criteria (p = 0.001; optimal cutoff 100 ng/ml) and beyond them (p = 0.023; optimal cutoff 100 ng/ml) but not in patients within the Milan criteria (p = 0.834). Patients within either UCSF and Up-to-7 criteria with AFP level <100 ng/ml exhibited superior (100 %) 5-year recurrence-free survival-significantly higher than those within UCSF (p = 0.005) or Up-to-7 (p = 0.001) criteria with AFP levels higher than the estimated cutoffs or beyond with AFP levels less than the estimated cutoffs.
conclusionsCombining the UCSF and Up-to-7 criteria with an AFP level <100 ng/ml is associated with minimal risk of tumor recurrence. Hence, this combination might be useful for selecting HCC patients for LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.